We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term survivors of glioblastoma: clinical features and molecular analysis.
- Authors
Sonoda, Yukihiko; Kumabe, Toshihiro; Watanabe, Mika; Nakazato, Yoichi; Inoue, Tomoo; Kanamori, Masayuki; Tominaga, Teiji
- Abstract
Glioblastoma is a highly lethal neoplasm with a median survival of 12–14 months; only 2–5% of patients survive >3 years. At our institute, patients with glioblastoma are initially treated with maximum tumor resection followed by radiation and the intravenous injection of nimustine hydrochloride (ACNU). Using this strategy, 18 of 123 (14.6%) patients treated at our hospital survived >3 years; 7 manifested no recurrence, and the other 11 had early recurrence and received additional therapies. To identify factors associated with prolonged survival, we compared these patients with 21 short-term (<1.5 years) glioblastoma survivors. In the long-term survivors, the MGMT promoter methylation was significantly more frequent. The rate of p53 mutation was lower, and the rate of PTEN mutations and the proliferation index were slightly higher in short-term survivors. By multivariate analysis, we found that a younger age and MGMT promoter methylation were significant favorable factors in patients with glioblastoma.
- Subjects
GLIOBLASTOMA multiforme; SURGICAL excision; TUMORS; INTRAVENOUS therapy; GLIOMAS; PATIENTS
- Publication
Acta Neurochirurgica, 2009, Vol 151, Issue 11, p1349
- ISSN
0001-6268
- Publication type
Article
- DOI
10.1007/s00701-009-0387-1